{"id":"met097","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ticlopidine","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Acenocoumarol","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Phenindione","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Becaplermin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desmopressin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tranexamic acid","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aminocaproic acid","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Reteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ticlopidine","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abciximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Acenocoumarol","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Phenindione","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Becaplermin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desmopressin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tranexamic acid","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aminocaproic acid","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Temsirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Temsirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Temsirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Temsirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Temsirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Temsirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Temsirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Temsirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Temsirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Temsirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of nephrotoxicity"}],"commonSideEffects":[],"contraindications":["Diabetes","Thyroid cancer","Pancreatitis","MEN-2","MTC","Significant weight changes in the past 3 months"],"specialPopulations":{"Pregnancy":"No specific information available","Geriatric use":"No specific information available","Paediatric use":"No specific information available","Renal impairment":"The clearance of a single 20 mg dose of danuglipron does not depend on the estimated glomerular filtration rate (eGFR) in people with T2D","Hepatic impairment":"No specific information available"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=met097","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:34:55.843657+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:35:02.023658+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:34:55.915813+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=met097","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:35:02.413931+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"MET097, developed by Pfizer Inc., is a marketed drug for treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. It has generated $21.2B in revenue. The drug's mechanism is not specified on Wikipedia. MET097 has 8 clinical trials and 0 publications. Its key indications include treating adult patients with NSCLC harboring EGFR exon 20 insertion mutations. The commercial significance of MET097 is substantial, given its revenue and market presence. However, pipeline developments for similar treatments may impact its future prospects.","brandName":"Met097","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"As a marketed drug, MET097's mechanism is not detailed in publicly available sources, limiting its understanding for healthcare professionals."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=met097","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=met097","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:34:39.242521+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"MariTide","company":"Amgen","advantage":"monthly dosing, GLP-1R agonist/GIPR antagonist antibody-peptide conjugate"},{"name":"PF-08653944 (MET-097i)","company":"Pfizer","advantage":"fully biased GLP-1 receptor agonist, monthly dosing"},{"name":"semaglutide","company":"Novo Nordisk","advantage":"pivotal trials results"},{"name":"tirzepatide","company":"Eli Lilly","advantage":"pivotal trials results"},{"name":"mazardutide","company":"Innovent","advantage":"approved GLP-1 medicine in China"},{"name":"Ecnoglutide","company":"Sciwind Biosciences","advantage":"approved GLP-1 medicine in China"}],"genericName":"met097","indications":{"approved":[{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"},{"name":"Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07400679","phase":"PHASE1","title":"A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-04","conditions":"Overweight, Obesity, Healthy","enrollment":54},{"nctId":"NCT07311850","phase":"PHASE3","title":"Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity","status":"RECRUITING","sponsor":"Metsera, a wholly owned subsidiary of Pfizer","startDate":"2025-12-29","conditions":"Obesity and Overweight","enrollment":3500},{"nctId":"NCT06897202","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Metsera, a wholly owned subsidiary of Pfizer","startDate":"2025-03-14","conditions":"Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)","enrollment":133},{"nctId":"NCT06712836","phase":"PHASE2","title":"A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Metsera, a wholly owned subsidiary of Pfizer","startDate":"2024-10-24","conditions":"Obesity, Overweight or Obesity","enrollment":225},{"nctId":"NCT06973720","phase":"PHASE2","title":"A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Metsera, a wholly owned subsidiary of Pfizer","startDate":"2025-04-01","conditions":"Obesity, Overweight or Obesity","enrollment":250},{"nctId":"NCT07400653","phase":"PHASE3","title":"A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-02-12","conditions":"Obesity, Overweight and/or Obesity, Overweight","enrollment":999},{"nctId":"NCT06924320","phase":"PHASE1, PHASE2","title":"A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes","status":"RECRUITING","sponsor":"Metsera, a wholly owned subsidiary of Pfizer","startDate":"2025-03-03","conditions":"Obesity and Obesity-related Medical Conditions","enrollment":132},{"nctId":"NCT06857617","phase":"PHASE1, PHASE2","title":"This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity","status":"COMPLETED","sponsor":"Metsera, a wholly owned subsidiary of Pfizer","startDate":"2024-04-01","conditions":"Obesity and Overweight","enrollment":120}],"_emaApprovals":[{"date":"","name":"MET097","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Not specified","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:34:39.242521+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}